By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Amivantamab > Amivantamab Side Effects
Miscellaneous antineoplastics

Amivantamab Side Effects

Applies to amivantamab: intravenous solution.

Serious side effects of Amivantamab

Along with its needed effects, amivantamab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking amivantamab:

More common

  • Back pain
  • bleeding gums
  • blistering, crusting, irritation, itching, or reddening of the skin
  • blood in the urine
  • bloody nose
  • burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings
  • chest pain or tightness
  • chills
  • cough
  • coughing or spitting up blood
  • cracked, dry, or scaly skin
  • dry, itching skin
  • fever
  • flushing
  • headache
  • loosening of the fingernails
  • muscle or bone pain
  • nausea and vomiting
  • nerve pain
  • rash with flat lesions or small raised lesions on the skin
  • redness or soreness around the fingernails
  • sneezing
  • swelling
  • trouble breathing
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Less common

  • Anxiety
  • dizziness or lightheadedness
  • fainting
  • fast heartbeat
  • general feeling of discomfort or illness
  • thickening of bronchial secretions

Rare

  • Blistering, peeling, or loosening of the skin
  • blurred vision or other change in vision
  • diarrhea
  • eye redness, irritation, or pain
  • red irritated eyes
  • red skin lesions, often with a purple center
  • sensitivity of the eye to light
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • tearing
  • unusual tiredness or weakness

Other side effects of Amivantamab

Some side effects of amivantamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Canker sores
  • chapped, red, or swollen lips
  • constipation
  • decreased appetite
  • difficulty in moving
  • lack or loss of strength
  • muscle aches, cramps, or stiffness
  • pain in the arms or legs
  • pain in the joints
  • redness, swelling, or soreness of the tongue
  • scaling, redness, burning, pain, or other signs of inflammation of the lips
  • stomach pain
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to amivantamab: intravenous solution.

Dermatologic

Rash occurred in 75% of patients treated with this drug, including Grade 3 rash in 3.7% of patients. Rash generally developed within the first 4 weeks of therapy with a median time to onset of 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 7% of patients; this drug was permanently discontinued due to rash in 0.7% of patients.

Paronychia occurred in 43% of patients treated with this drug, including Grade 3 paronychia in 2% of patients. The median time from onset of paronychia to complete resolution was 235 days (range: 26 to 443 days). Paronychia leading to discontinuation of this drug occurred in 2% of patients.[Ref]

Very common (10% or more): Rash (includes acne, dermatitis, acneiform dermatitis, eczema, asteatotic eczema, erythema, erythema multiforme, folliculitis, impetigo, palmar-plantar erythrodysesthesia syndrome, perineal rash, perioral dermatitis, pustule, rash, erythematous rash, macular rash, maculopapular rash, papular rash, pruritic rash, pustular rash, vesicular rash, skin exfoliation, skin lesion, toxic epidermal necrolysis; up to 84%), paronychia (up to 50%), pruritus (up to 18%), dry skin (includes dry skin, eczema, asteatotic eczema, skin fissures, xeroderma; up to 14%), nail toxicity (includes ingrowing nail, nail bed infection, nail cuticle fissure, nail disorder, nail ridging, onychoclasis, onycholysis, paronychia)

Uncommon (0.1% to 1%): Toxic epidermal necrolysis[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 36%), stomatitis (includes aphthous ulcer, cheilitis, glossitis, lip ulceration, mouth ulceration, mucosal inflammation, pharyngeal inflammation, stomatitis; up to 26%), constipation (up to 23%), vomiting (up to 22%), diarrhea (up to 16%), abdominal pain (includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, epigastric discomfort, gastrointestinal pain; up to 11%)[Ref]

Hematologic

Very common (10% or more): Decreased lymphocytes (up to 36%), hemorrhage (includes epistaxis, gingival bleeding, hematuria, hemoptysis, hemorrhage, mouth hemorrhage, mucosal hemorrhage; up to 19%)[Ref]

Hepatic

Very common (10% or more): Increased ALT (up to 38%), increased AST (up to 33%), increased GGT (up to 27%)[Ref]

Immunologic

Common (1% to 10%): Positive for anti-drug antibodies[Ref]

Metabolic

Very common (10% or more): Hypoalbuminemia/decreased albumin (up to 79%), increased glucose (up to 56%), hypomagnesemia/decreased magnesium (up to 27%), hypokalemia/decreased potassium (up to 26%), decreased appetite (up to 15%), hypocalcemia[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, noncardiac chest pain, pain in extremity, spinal pain; up to 47%), myalgia[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (includes hypoesthesia, neuralgia, paresthesia, peripheral sensory neuropathy; up to 13%), dizziness (includes dizziness, exertional dizziness, vertigo; up to 12%), headache (includes headache, migraine; 10%)[Ref]

Ocular

Common (1% to 10%): Visual impairment (includes blurred vision, reduced visual acuity, visual impairment), growth of eyelashes (includes growth of eyelashes, trichomegaly), keratitis, other eye disorders (includes blepharitis, conjunctival hyperemia, corneal irritation, dry eye, episcleritis, eye disorder, eye pruritus, noninfective conjunctivitis, ocular hyperemia)

Uncommon (0.1% to 1%): Keratitis, uveitis

Frequency not reported: Ocular toxicity[Ref]

In the safety population, keratitis and uveitis occurred in 0.7% and 0.3% of patients treated with this drug, respectively; all events were Grade 1 to 2.

According to some authorities, eye disorders (including keratitis [0.4%]) occurred in 12% of patients treated with this drug; most events were Grade 1 or 2, with Grade 3 events occurring in 0.2% of patients. Keratitis led to dose interruption in 0.2% of patients, and blurred vision led to discontinuation of this drug in 0.2% of patients.[Ref]

Other

Very common (10% or more): Infusion-related reaction (IRR; up to 67%), increased alkaline phosphatase (up to 53%), fatigue (includes asthenia, fatigue; up to 33%), decreased phosphate (up to 33%), edema (includes eye edema, eyelid edema, face edema, generalized edema, lip edema, localized edema, edema, peripheral edema, periorbital edema, periorbital swelling, peripheral swelling, swelling face; up to 27%), decreased sodium (up to 27%), pyrexia (up to 13%)[Ref]

In the safety population, IRR occurred in 66% of patients treated with this drug; among patients receiving treatment, 65% had an IRR with the Week 1 Day 1 infusion, 3.4% with the Week 1 Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRR, 97% were Grade 1 to 2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after the start of the infusion. Infusion was modified due to IRR in 62% of patients; 1.3% of patients permanently discontinued this drug due to IRR.[Ref]

Renal

Very common (10% or more): Increased creatinine (up to 46%)[Ref]

Respiratory

In the safety population, ILD/pneumonitis occurred in 3.3% of patients treated with this drug, including Grade 3 ILD/pneumonitis in 0.7% of patients; 3 patients (1%) discontinued this drug due to ILD/pneumonitis.[Ref]

Very common (10% or more): Dyspnea (includes dyspnea, exertional dyspnea; up to 37%), cough (includes cough, productive cough, upper airway cough syndrome; up to 25%), pneumonia (includes atypical pneumonia, lower respiratory tract infection, pneumonia, aspiration pneumonia, pulmonary sepsis; 10%)

Common (1% to 10%): Interstitial lung disease (ILD)

Frequency not reported: ILD/pneumonitis[Ref]

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by